Aetna modified CPB 0833 for hematopoietic cell transplantation in Waldenstrom macroglobulinemia, effective December 10, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated CPB 0833 to define coverage for hematopoietic cell transplantation (HCT) in Waldenstrom macroglobulinemia. The policy draws a hard line: autologous transplantation (CPT 38232 and 38241) is medically necessary as salvage treatment for chemo-sensitive disease. Allogeneic transplantation (CPT 38230 and 38240) is experimental and not covered. If your team bills either type under ICD-10 C88.0 or C88.1, this Aetna hematopoietic cell transplantation coverage policy governs what gets paid and what gets denied.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Hematopoietic Cell Transplantation for Waldenstrom Macroglobulinemia |
| Policy Code | CPB 0833 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology, Oncology, Bone Marrow Transplant Programs, Hospital Outpatient/Inpatient Billing |
| Key Action | Confirm transplant type (autologous vs. allogeneic) before submitting claims under CPT 38230, 38232, 38240, or 38241 |
Aetna Hematopoietic Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025
The coverage policy under CPB 0833 Aetna turns on a single clinical variable: the type of transplant. Get that right and you have a path to reimbursement. Get it wrong and you're looking at a claim denial before clinical review even begins.
For autologous HCT, Aetna defines medical necessity with two conditions. First, the transplant must be used as salvage treatment. Second, the patient's Waldenstrom macroglobulinemia must be chemo-sensitive. Both conditions must be present. If the disease is refractory or the transplant is being used in an earlier line of treatment, medical necessity is not established under this policy.
CPT 38232 (bone marrow harvesting for transplantation, autologous) and CPT 38241 (bone marrow or blood-derived peripheral stem cell transplantation, autologous) are the covered procedure codes when both selection criteria are met. HCPCS S2150, which covers harvest of bone marrow or blood-derived stem cells for either autologous or allogeneic use, is also covered when selection criteria are met.
Prior authorization is almost certainly required for transplant procedures of this complexity and cost. The policy does not waive standard Aetna prior auth processes. Before scheduling, confirm prior authorization requirements directly with Aetna for the member's specific plan. If you're unsure how this applies to your patient mix, loop in your compliance officer before the December 10, 2025 effective date.
Aetna Hematopoietic Cell Transplantation Exclusions and Non-Covered Indications
Allogeneic HCT for Waldenstrom macroglobulinemia is experimental, investigational, and unproven under CPB 0833. Aetna's position is direct: effectiveness for this indication has not been established. That's not a soft exclusion — it's a firm coverage denial for CPT 38230 and CPT 38240.
CPT 38230 is bone marrow harvesting for transplantation, allogeneic. CPT 38240 is bone marrow or blood-derived peripheral stem cell transplantation, allogeneic. Both are explicitly not covered under this policy for Waldenstrom macroglobulinemia, regardless of disease stage, prior treatment history, or donor availability.
This is the real issue for transplant programs with active allogeneic protocols. If your institution is offering allogeneic HCT for this diagnosis under any clinical rationale, reimbursement from Aetna will not follow. Claims submitted under CPT 38230 or 38240 with C88.0 or C88.1 will be denied. An appeal citing medical necessity will not succeed under the current policy — Aetna's experimental designation blocks that path. If your program believes allogeneic HCT is appropriate for a specific patient, get your compliance officer and billing consultant involved before the claim goes out.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Autologous HCT as salvage treatment for chemo-sensitive Waldenstrom macroglobulinemia | Covered | CPT 38232, 38241; HCPCS S2150; ICD-10 C88.0, C88.1 | Both selection criteria must be met: salvage setting and chemo-sensitive disease. Prior auth expected. |
| Allogeneic HCT for Waldenstrom macroglobulinemia | Not Covered — Experimental/Investigational | CPT 38230, 38240; ICD-10 C88.0, C88.1 | Deemed experimental. Effectiveness not established. Claims will be denied. No appeal path under medical necessity. |
Aetna Hematopoietic Cell Transplantation Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your active Waldenstrom macroglobulinemia cases before December 10, 2025. Pull all cases coded C88.0 and C88.1 with pending or planned transplant procedures. Flag each one by transplant type. Autologous cases need to meet salvage and chemo-sensitivity criteria. Allogeneic cases need a different conversation entirely. |
| 2 | Separate your charge capture for autologous and allogeneic procedures right now. CPT 38232 and 38241 are covered under selection criteria. CPT 38230 and 38240 are not covered for this diagnosis. If your charge capture system defaults to a generic transplant code or bundles harvesting and infusion, fix that mapping before the effective date of December 10, 2025. |
| 3 | Verify prior authorization for every autologous HCT case under this policy. Aetna's standard prior authorization requirements apply. "The policy covers it" does not mean prior auth is waived. A claim for CPT 38241 without prior auth on file is a denial waiting to happen, even when the clinical criteria are perfectly met. |
| 4 | Brief your clinical documentation team on the two medical necessity triggers. Salvage setting and chemo-sensitivity are both required. Your documentation needs to support both, explicitly. A note that says "patient failed prior therapy" is not enough. The record should show the disease responded to chemotherapy (chemo-sensitive) and that this transplant is being used as a salvage approach. |
| 5 | Stop submitting allogeneic HCT claims for Waldenstrom macroglobulinemia under Aetna and expecting appeal success. CPT 38230 and 38240 are blocked at the policy level under CPB 0833. Appeals citing clinical literature or individual medical necessity will not reverse an experimental designation. If you have a patient situation you believe warrants an exception, talk to your compliance officer and consider a peer-to-peer with the Aetna medical director before the claim is submitted — not after the denial. |
| 6 | Confirm how HCPCS S2150 is mapped in your system. S2150 covers harvest of bone marrow or blood-derived stem cells for both autologous and allogeneic use. Under CPB 0833, it's covered when selection criteria are met — which applies to the autologous indication only in this context. Make sure your billing guidelines flag that S2150 submitted with an allogeneic transplant for this diagnosis will still follow the same coverage rule as CPT 38230 and 38240. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hematopoietic Cell Transplantation Under CPB 0833
Covered CPT and HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 38232 | CPT | Bone marrow harvesting for transplantation; autologous |
| 38241 | CPT | Bone marrow or blood-derived peripheral stem cell transplantation; autologous |
| S2150 | HCPCS | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvest |
Selection criteria: autologous HCT used as salvage treatment for chemo-sensitive Waldenstrom macroglobulinemia. Both criteria must be documented.
Not Covered — Experimental and Investigational Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 38230 | CPT | Bone marrow harvesting for transplantation; allogeneic | Allogeneic HCT considered experimental, investigational, or unproven for Waldenstrom macroglobulinemia |
| 38240 | CPT | Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic | Allogeneic HCT considered experimental, investigational, or unproven for Waldenstrom macroglobulinemia |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C88.0 | Waldenstrom macroglobulinemia |
| C88.1 | Waldenstrom macroglobulinemia |
Both C88.0 and C88.1 map to the same clinical diagnosis in this policy. Use either code per your facility's documentation guidelines. The coverage rules under CPB 0833 apply identically to both.
Get the Full Picture for CPT 38232
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.